These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 29684468)

  • 1. Bile acid regulation: A novel therapeutic strategy in non-alcoholic fatty liver disease.
    Yu Q; Jiang Z; Zhang L
    Pharmacol Ther; 2018 Oct; 190():81-90. PubMed ID: 29684468
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Associations between Circulating Bile Acids and the Muscle Volume in Patients with Non-alcoholic Fatty Liver Disease (NAFLD).
    Kobayashi Y; Hara N; Sugimoto R; Mifuji-Moroka R; Tanaka H; Eguchi A; Iwasa M; Hasegawa H; Iwata K; Takei Y; Taguchi O
    Intern Med; 2017; 56(7):755-762. PubMed ID: 28381740
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel function of histamine signaling via histamine receptors in cholesterol and bile acid metabolism: Histamine H2 receptor protects against nonalcoholic fatty liver disease.
    Yamada S; Guo X; Wang KY; Tanimoto A; Sasaguri Y
    Pathol Int; 2016 Jul; 66(7):376-85. PubMed ID: 27321390
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bile Acids and Dysbiosis in Non-Alcoholic Fatty Liver Disease.
    Mouzaki M; Wang AY; Bandsma R; Comelli EM; Arendt BM; Zhang L; Fung S; Fischer SE; McGilvray IG; Allard JP
    PLoS One; 2016; 11(5):e0151829. PubMed ID: 27203081
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Disturbed Vitamin A Metabolism in Non-Alcoholic Fatty Liver Disease (NAFLD).
    Saeed A; Dullaart RPF; Schreuder TCMA; Blokzijl H; Faber KN
    Nutrients; 2017 Dec; 10(1):. PubMed ID: 29286303
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Why Bile Acids Are So Important in Non-Alcoholic Fatty Liver Disease (NAFLD) Progression.
    Gottlieb A; Canbay A
    Cells; 2019 Oct; 8(11):. PubMed ID: 31671697
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting the Gut Microbiota for the Treatment of Non-Alcoholic Fatty Liver Disease.
    Mouzaki M; Bandsma R
    Curr Drug Targets; 2015; 16(12):1324-31. PubMed ID: 25882223
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Current Understanding of FXR in NAFLD: The multifaceted regulatory role of FXR and novel lead discovery for drug development.
    Tang Y; Fan Y; Wang Y; Wang D; Huang Q; Chen T; Cao X; Wen C; Shen X; Li J; You Y
    Biomed Pharmacother; 2024 Jun; 175():116658. PubMed ID: 38701562
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fibroblast Growth Factor 19: Potential modulation of hepatic metabolism for the treatment of non-alcoholic fatty liver disease.
    Sciarrillo CM; Keirns BH; Koemel NA; Anderson KL; Emerson SR
    Liver Int; 2021 May; 41(5):894-904. PubMed ID: 33506572
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inulin activates FXR-FGF15 signaling and further increases bile acids excretion in non-alcoholic fatty liver disease mice.
    Wang R; Ren Y; Bao T; Wang T; Li Y; Liu Y; Zhang X; Yang S; Wang H
    Biochem Biophys Res Commun; 2022 Apr; 600():156-162. PubMed ID: 35240510
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A targeted analysis reveals relevant shifts in the methylation and transcription of genes responsible for bile acid homeostasis and drug metabolism in non-alcoholic fatty liver disease.
    Schiöth HB; Boström A; Murphy SK; Erhart W; Hampe J; Moylan C; Mwinyi J
    BMC Genomics; 2016 Jun; 17():462. PubMed ID: 27301979
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutic modulation of the bile acid pool by Cyp8b1 knockdown protects against nonalcoholic fatty liver disease in mice.
    Chevre R; Trigueros-Motos L; Castaño D; Chua T; Corlianò M; Patankar JV; Sng L; Sim L; Juin TL; Carissimo G; Ng LFP; Yi CNJ; Eliathamby CC; Groen AK; Hayden MR; Singaraja RR
    FASEB J; 2018 Jul; 32(7):3792-3802. PubMed ID: 29481310
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Exposure to environmental contaminants is associated with altered hepatic lipid metabolism in non-alcoholic fatty liver disease.
    Sen P; Qadri S; Luukkonen PK; Ragnarsdottir O; McGlinchey A; Jäntti S; Juuti A; Arola J; Schlezinger JJ; Webster TF; Orešič M; Yki-Järvinen H; Hyötyläinen T
    J Hepatol; 2022 Feb; 76(2):283-293. PubMed ID: 34627976
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bile Acid Receptors and the Gut-Liver Axis in Nonalcoholic Fatty Liver Disease.
    Xue R; Su L; Lai S; Wang Y; Zhao D; Fan J; Chen W; Hylemon PB; Zhou H
    Cells; 2021 Oct; 10(11):. PubMed ID: 34831031
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recent insights into farnesoid X receptor in non-alcoholic fatty liver disease.
    Xu JY; Li ZP; Zhang L; Ji G
    World J Gastroenterol; 2014 Oct; 20(37):13493-500. PubMed ID: 25309079
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ganoderma Lucidum Polysaccharide Peptide Alleviates Hepatoteatosis via Modulating Bile Acid Metabolism Dependent on FXR-SHP/FGF.
    Zhong D; Xie Z; Huang B; Zhu S; Wang G; Zhou H; Lin S; Lin Z; Yang B
    Cell Physiol Biochem; 2018; 49(3):1163-1179. PubMed ID: 30196282
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The intrahepatic expression levels of bile acid transporters are inversely correlated with the histological progression of nonalcoholic fatty liver disease.
    Okushin K; Tsutsumi T; Enooku K; Fujinaga H; Kado A; Shibahara J; Fukayama M; Moriya K; Yotsuyanagi H; Koike K
    J Gastroenterol; 2016 Aug; 51(8):808-18. PubMed ID: 26601667
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Alpinetin improved high fat diet-induced non-alcoholic fatty liver disease (NAFLD) through improving oxidative stress, inflammatory response and lipid metabolism.
    Zhou Y; Ding YL; Zhang JL; Zhang P; Wang JQ; Li ZH
    Biomed Pharmacother; 2018 Jan; 97():1397-1408. PubMed ID: 29156529
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bile acids associate with specific gut microbiota, low-level alcohol consumption and liver fibrosis in patients with non-alcoholic fatty liver disease.
    Adams LA; Wang Z; Liddle C; Melton PE; Ariff A; Chandraratna H; Tan J; Ching H; Coulter S; de Boer B; Christophersen CT; O'Sullivan TA; Morrison M; Jeffrey GP
    Liver Int; 2020 Jun; 40(6):1356-1365. PubMed ID: 32243703
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gender-Specific Bile Acid Profiles in Non-Alcoholic Fatty Liver Disease.
    Fitzinger J; Rodriguez-Blanco G; Herrmann M; Borenich A; Stauber R; Aigner E; Mangge H
    Nutrients; 2024 Jan; 16(2):. PubMed ID: 38257143
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.